Zacks Investment Research upgraded shares of CRYOLIFE INC (CRY) from NEUTRAL to OUTPERFORM on August 01, 2012, with a target price of $5.90.
CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The company's BioGlue surgical adhesive, the company marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The company also manufactures CryoLife- O'Brien and CryoLife-Ross stentless porcine heart valves which are distributed within the European Community. (PRESS RELEASE)
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CRYOLIFE INC (CRY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment